

## MAYFLOWERS-0B-20: A Prospective Study Evaluating Maternal and Fetal Outcomes in the Era of ModulatorS (MAYFLOWERS)

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Female

**Age Group:** 16 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- at least 16 years old - pregnant, intending to continue pregnancy - enrolled in the Cystic Fibrosis Foundation Patient Registry (CFFPR)

---

**Exclusion Criteria:**

- none

### Conditions & Interventions

**Conditions:**

Rare Diseases, Respiratory System

**Keywords:**

Clinics and Surgery Center (CSC), Cystic Fibrosis, Pregnancy

### More Information

**Description:** This study is being done to look at how pregnancy affects the health of women with cystic fibrosis (CF) and to look at the health of babies born to women with CF. It is expected that most but not all women will be taking the newest CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator medication called TRIKAFTA®. It is not known how this medication will affect the health of mother and infant.

**Study Contact:** Mary Bailey - mpbailey@umn.edu

**Principal Investigator:** Joanne Billings

**IRB Number:** SITE00001209

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.